Moleculin Biotech is trading 5.62% up at $0.47 amid a stronger broader market, with the Nasdaq Composite up 0.66%.
- No verified company-specific announcement dated August 12, 2026 was identified.
- Recent volatility reflects the June MIRACLE trial update and August 3 completion of a $9.3 million financing; neither is a new catalyst.
- The stock has gained across three consecutive sessions, suggesting continued speculative trading and elevated volatility rather than a confirmed fundamental repricing.